SANOFI-ADR (SNY) Stock Price, Quote, News and Overview
NASDAQ:SNY - Nasdaq - US80105N1054 - ADR - Currency: USD
SNY Quote, Performance and Key Statistics
52.51
-0.39 (-0.74%)
The current stock price of SNY is 52.51 USD. In the past month the price decreased by -1.92%. In the past year, price increased by 8.18%.
SNY Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 51.98 | 678.00B | ||
| JNJ | JOHNSON & JOHNSON | 15.19 | 367.19B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 19.48 | 302.61B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.54 | 222.20B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 18.8 | 216.87B | ||
| MRK | MERCK & CO. INC. | 9.99 | 195.88B | ||
| PFE | PFIZER INC | 7.18 | 130.67B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 6.41 | 95.71B | ||
| GSK | GSK PLC-SPON ADR | 7.06 | 78.75B | ||
| ZTS | ZOETIS INC | 26.91 | 72.25B | ||
| HLN | HALEON PLC-ADR | 22.57 | 49.87B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 26.2 | 45.35B |
Related stock screener links
About SNY
Company Profile
Sanofi engages in the research, production, and distribution of pharmaceutical products. The company is headquartered in Paris, Ile-De-France and currently employs 84,587 full-time employees. The company went IPO on 2002-07-01. The firm focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme.
Company Info
SANOFI-ADR
46 Avenue de la Grande Armee
Paris ILE-DE-FRANCE 75008 FR
CEO: Paul Hudson
Employees: 82878
Phone: 33153774000
SANOFI-ADR / SNY FAQ
What is the stock price of SANOFI-ADR today?
The current stock price of SNY is 52.51 USD. The price decreased by -0.74% in the last trading session.
What is the ticker symbol for SANOFI-ADR stock?
The exchange symbol of SANOFI-ADR is SNY and it is listed on the Nasdaq exchange.
On which exchange is SNY stock listed?
SNY stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for SANOFI-ADR stock?
29 analysts have analysed SNY and the average price target is 67.56 USD. This implies a price increase of 28.67% is expected in the next year compared to the current price of 52.51. Check the SANOFI-ADR stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is SANOFI-ADR worth?
SANOFI-ADR (SNY) has a market capitalization of 128.55B USD. This makes SNY a Large Cap stock.
How many employees does SANOFI-ADR have?
SANOFI-ADR (SNY) currently has 82878 employees.
What are the support and resistance levels for SANOFI-ADR (SNY) stock?
SANOFI-ADR (SNY) has a support level at 49.66 and a resistance level at 52.81. Check the full technical report for a detailed analysis of SNY support and resistance levels.
Is SANOFI-ADR (SNY) expected to grow?
The Revenue of SANOFI-ADR (SNY) is expected to grow by 1.53% in the next year. Check the estimates tab for more information on the SNY EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy SANOFI-ADR (SNY) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of SNY, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of SNY, evaluating the profitability, health, valuation and growth aspects
- SANOFI-ADR (SNY) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- SANOFI-ADR (SNY) Sales and EPS estimates to see what analysts future expectations are.
- SANOFI-ADR (SNY) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- SANOFI-ADR (SNY) Insider and Institutional Ownership to learn about the owners and their transactions.
- SANOFI-ADR (SNY) Stock Chart to make your own analysis
- SANOFI-ADR (SNY) Latest news and press-releases to stay up to date.
Does SANOFI-ADR (SNY) stock pay dividends?
SANOFI-ADR (SNY) has a dividend yield of 4.36%. The yearly dividend amount is currently 2.14. Check the full fundamental report for a detailed analysis of SNY dividend history, reliability and sustainability.
When does SANOFI-ADR (SNY) report earnings?
SANOFI-ADR (SNY) will report earnings on 2025-07-31, before the market open.
What is the Price/Earnings (PE) ratio of SANOFI-ADR (SNY)?
The PE ratio for SANOFI-ADR (SNY) is 13.71. This is based on the reported non-GAAP earnings per share of 3.83 and the current share price of 52.51 USD. Check the full fundamental report for a full analysis of the valuation metrics for SNY.
What is the Short Interest ratio of SANOFI-ADR (SNY) stock?
The outstanding short interest for SANOFI-ADR (SNY) is 0.16% of its float. Check the ownership tab for more information on the SNY short interest.
SNY Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to SNY. When comparing the yearly performance of all stocks, SNY turns out to be only a medium performer in the overall market: it outperformed 64.05% of all stocks.
SNY Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to SNY. While SNY belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health.
SNY Financial Highlights
Over the last trailing twelve months SNY reported a non-GAAP Earnings per Share(EPS) of 3.83. The EPS decreased by -12.99% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 12.97% | ||
| ROA | 9% | ||
| ROE | 15.37% | ||
| Debt/Equity | 0.17 |
SNY Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 80% to SNY. The Buy consensus is the average rating of analysts ratings from 29 analysts.
For the next year, analysts expect an EPS growth of 8.37% and a revenue growth 1.53% for SNY